Track Spero Therapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Spero Therapeutics, Inc. SPRO · Stock Open Spero Therapeutics, Inc. in new tab

1.14 USD
P/E
8.07
EPS
0.14
P/B
1.49
ROE
19.17
Beta
1.48
Target Price
5.00 USD
Loading chart...
Key Metrics
Earnings dateNov. 12, 2026
P/E8.07
EPS0.14
Book Value0.76
Price to Book1.49
Debt/Equity4.62
% Insiders22.610%
Growth
Revenue Growth-0.96%
Estimates
Forward P/E-1.02
Forward EPS-1.11
Target Mean Price5.00

DCF Valuation

Tweak assumptions to recompute fair value for Spero Therapeutics, Inc. (SPRO)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Spero Therapeutics, Inc. Logo Spero Therapeutics, Inc. Analysis (SPRO)

United States Health Care Official Website Stock

Is Spero Therapeutics, Inc. a good investment? Spero Therapeutics, Inc. (SPRO) is currently trading at 1.14 USD. Market analysts have a consensus price target of 5.00 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 8.07. This relatively low multiple may signal that Spero Therapeutics, Inc. is undervalued compared to historical market norms.

Earnings Schedule: Spero Therapeutics, Inc. is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is -1.11.

Investor FAQ

Does Spero Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Spero Therapeutics, Inc.?

Spero Therapeutics, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of 0.14.

Company Profile

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Exchange Ticker
NMS (United States) SPRO
FRA (Germany) 2HA.F
Trades
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
2015
0.06 USD
Oct. 7, 2015 0.0150
July 7, 2015 0.0150
April 7, 2015 0.0150
Jan. 6, 2015 0.0150
2014
0.06 USD
Oct. 7, 2014 0.0150
July 7, 2014 0.0150
April 7, 2014 0.0150
Jan. 6, 2014 0.0150
2013
0.06 USD
Oct. 7, 2013 0.0150
July 5, 2013 0.0150
April 5, 2013 0.0150
Jan. 7, 2013 0.0100
2012
0.04 USD
Oct. 5, 2012 0.0100
July 6, 2012 0.0100
April 4, 2012 0.0100
Jan. 5, 2012 0.0100
2011
0.03 USD
Oct. 5, 2011 0.0100
July 8, 2011 0.0100
April 4, 2011 0.0100
2010
0.04 USD
Dec. 31, 2010 0.0100
Oct. 11, 2010 0.0100
July 12, 2010 0.0100
April 11, 2010 0.0100
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion